for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-GW Pharma reports positive results for schizophrenia drug in mid-stage trial

Sept 15 (Reuters) - GW Pharmaceuticals Plc :

* Positive proof of concept data in schizophrenia

* Positive top line results from exploratory phase 2a placebo-controlled clinical trial of Cannabidiol (CBD) in 88 patients

* In trial, patients remained on their anti-psychotic medication and were randomized to receive CBD or placebo as adjunct therapy

* Majority of other endpoints in study were in favor of CBD and approached statistical significance in many cases

* Over a series of exploratory endpoints, CBD was consistently superior to placebo

* Safety profile of CBD was reassuring, with no serious adverse events

* Majority of other endpoints in study were in favor of CBD and approached statistical significance in many cases Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up